The HIV-1 capsid core is an opportunistic nuclear import receptor.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
24 06 2023
Historique:
received: 16 02 2018
accepted: 01 06 2023
medline: 26 6 2023
pubmed: 25 6 2023
entrez: 24 6 2023
Statut: epublish

Résumé

The movement of viruses and other large macromolecular cargo through nuclear pore complexes (NPCs) is poorly understood. The human immunodeficiency virus type 1 (HIV-1) provides an attractive model to interrogate this process. HIV-1 capsid (CA), the chief structural component of the viral core, is a critical determinant in nuclear transport of the virus. HIV-1 interactions with NPCs are dependent on CA, which makes direct contact with nucleoporins (Nups). Here we identify Nup35, Nup153, and POM121 to coordinately support HIV-1 nuclear entry. For Nup35 and POM121, this dependence was dependent cyclophilin A (CypA) interaction with CA. Mutation of CA or removal of soluble host factors changed the interaction with the NPC. Nup35 and POM121 make direct interactions with HIV-1 CA via regions containing phenylalanine glycine motifs (FG-motifs). Collectively, these findings provide additional evidence that the HIV-1 CA core functions as a macromolecular nuclear transport receptor (NTR) that exploits soluble host factors to modulate NPC requirements during nuclear invasion.

Identifiants

pubmed: 37355754
doi: 10.1038/s41467-023-39146-5
pii: 10.1038/s41467-023-39146-5
pmc: PMC10290713
doi:

Substances chimiques

Nuclear Pore Complex Proteins 0
Capsid Proteins 0
POM121 protein, human 0
Membrane Glycoproteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3782

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI087390
Pays : United States
Organisme : NIGMS NIH HHS
ID : P50 GM103368
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI111809
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120860
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI117839
Pays : United States
Organisme : NIDA NIH HHS
ID : DP1 DA034990
Pays : United States
Organisme : NIAID NIH HHS
ID : U54 AI170856
Pays : United States

Informations de copyright

© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Références

Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):
pubmed: 33649225
Antimicrob Agents Chemother. 2013 Oct;57(10):4622-31
pubmed: 23817385
Science. 2008 Feb 15;319(5865):921-6
pubmed: 18187620
J Virol. 2007 Nov;81(21):11946-56
pubmed: 17715216
J Virol. 2012 Apr;86(8):4708-14
pubmed: 22301145
Cell Rep. 2020 Sep 29;32(13):108201
pubmed: 32997983
Retrovirology. 2014 Jan 30;11:11
pubmed: 24479545
J Cell Biol. 2011 Jul 11;194(1):27-37
pubmed: 21727197
Retrovirology. 2013 Feb 15;10:20
pubmed: 23414560
Viruses. 2013 Oct 07;5(10):2483-511
pubmed: 24103892
J Virol. 2004 Dec;78(23):12800-8
pubmed: 15542632
EMBO J. 2001 Jun 15;20(12):3272-81
pubmed: 11406603
Elife. 2018 Aug 07;7:
pubmed: 30084827
Mol Cell Biol. 2000 Oct;20(20):7798-812
pubmed: 11003674
J Virol. 1996 Jun;70(6):3551-60
pubmed: 8648689
Mol Syst Biol. 2013;9:648
pubmed: 23511206
J Virol. 1998 Jul;72(7):6004-13
pubmed: 9621063
Cell Rep. 2020 Mar 17;30(11):3766-3777.e6
pubmed: 32187548
PLoS Pathog. 2013;9(10):e1003693
pubmed: 24130490
J Virol. 2002 Dec;76(23):11889-903
pubmed: 12414931
PLoS Pathog. 2012;8(8):e1002896
pubmed: 22956906
Nat Commun. 2020 Nov 26;11(1):6165
pubmed: 33244008
Cell Host Microbe. 2010 Mar 18;7(3):221-33
pubmed: 20227665
Nat Commun. 2022 Oct 6;13(1):5879
pubmed: 36202818
PLoS Pathog. 2014 Oct 30;10(10):e1004459
pubmed: 25356722
J Virol. 2005 Jan;79(1):176-83
pubmed: 15596813
Cell. 2021 Feb 18;184(4):1032-1046.e18
pubmed: 33571428
Nat Microbiol. 2021 Apr;6(4):435-444
pubmed: 33649557
Nat Microbiol. 2019 Dec;4(12):2044-2051
pubmed: 31636416
J Virol. 2001 Jul;75(14):6537-46
pubmed: 11413321
Nat Commun. 2020 Jul 14;11(1):3505
pubmed: 32665593
Virology. 2001 Mar 30;282(1):154-67
pubmed: 11259198
PLoS Pathog. 2017 Aug 21;13(8):e1006570
pubmed: 28827840
J Biol Chem. 1996 Sep 20;271(38):23478-86
pubmed: 8798556
J Virol. 2018 Sep 12;92(19):
pubmed: 29997211
PLoS Pathog. 2010 Dec 09;6(12):e1001220
pubmed: 21170360
J Virol. 2012 Apr;86(7):3851-60
pubmed: 22301135
J Exp Med. 1999 Jun 7;189(11):1735-46
pubmed: 10359577
EMBO J. 2012 Oct 17;31(20):4072-84
pubmed: 22960634
Nat Med. 2019 Sep;25(9):1377-1384
pubmed: 31501601
Nat Microbiol. 2020 Sep;5(9):1088-1095
pubmed: 32483230
J Virol. 2011 Aug;85(15):7818-27
pubmed: 21593146
Virology. 2013 May 25;440(1):8-18
pubmed: 23523133
PLoS Pathog. 2014 Feb 20;10(2):e1003969
pubmed: 24586169
Cell. 2012 May 25;149(5):1035-47
pubmed: 22632968
PLoS Pathog. 2011 Dec;7(12):e1002439
pubmed: 22174692
Cell. 1993 Jun 18;73(6):1067-78
pubmed: 8513493
PLoS Pathog. 2007 Oct 26;3(10):1502-10
pubmed: 17967060
Science. 2007 Nov 30;318(5855):1412-6
pubmed: 18048681
Cell. 2008 Oct 3;135(1):49-60
pubmed: 18854154
iScience. 2021 Dec 09;25(1):103593
pubmed: 35005542
Elife. 2019 Jan 23;8:
pubmed: 30672737
J Exp Med. 1991 Dec 1;174(6):1477-82
pubmed: 1720811
Elife. 2021 Apr 27;10:
pubmed: 33904396

Auteurs

Guangai Xue (G)

Model Development Section, Cancer Innovation Laboratory, National Cancer Institute, Frederick, MD, 21702, USA.

Hyun Jae Yu (HJ)

Basic Science Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD, 21702, USA.

Cindy Buffone (C)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.

Szu-Wei Huang (SW)

Model Development Section, Cancer Innovation Laboratory, National Cancer Institute, Frederick, MD, 21702, USA.

KyeongEun Lee (K)

Model Development Section, Cancer Innovation Laboratory, National Cancer Institute, Frederick, MD, 21702, USA.

Shih Lin Goh (SL)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, 01605, USA.

Anna T Gres (AT)

Bond Life Sciences Center, Chemistry, University of Missouri, Columbia, MO, 65201, USA.

Mehmet Hakan Guney (MH)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, 01605, USA.

Stefan G Sarafianos (SG)

Bond Life Sciences Center, Chemistry, University of Missouri, Columbia, MO, 65201, USA.
Bond Life Sciences Center, MMI, Biochemistry, University of Missouri, Columbia, MO, 65201, USA.
Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA.

Jeremy Luban (J)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, 01605, USA.

Felipe Diaz-Griffero (F)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.

Vineet N KewalRamani (VN)

Model Development Section, Cancer Innovation Laboratory, National Cancer Institute, Frederick, MD, 21702, USA. vineet@mail.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH